What are the precautions when using ibrutinib (ibrutinib)? What contraindications or side effects should patients pay special attention to?

Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that is widely used to treat a variety of B Cell-related malignant tumors, such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenstrom's macroglobulinemia, etc. Although ibrutinib is effective in treating these diseases, its use is also associated with certain risks and side effects. Patients should pay special attention to the following precautions, contraindications and side effects when using ibrutinib to ensure the safety of treatment.

1. Cardiovascular health monitoring

Patients taking ibrutinib need to pay special attention to their cardiovascular health. Ibrutinib may cause atrial fibrillation and other cardiac arrhythmias, especially with long-term use. Atrial fibrillation is a common side effect that may increase a patient's risk of stroke, so patients should monitor their electrocardiogram regularly during treatment and pay attention to symptoms such as palpitations, chest pain, or shortness of breath. In addition, ibrutinib may increase the risk of hypertension, so patients with a history of hypertension should be used with special caution and the dose of blood pressure medication should be adjusted if necessary.

2. Risk of bleeding

Ibrutinib is an antiplatelet drug that may increase the risk of bleeding in some patients, especially those taking anticoagulants or those with a bleeding tendency. Common symptoms of bleeding include nosebleeds, bleeding gums, skin bruising, or blood in the urine. During the treatment process, patients should be particularly vigilant about these symptoms and report them to the doctor in time. If the patient is taking antiplatelet drugs or anticoagulants, the medication regimen must be adjusted under the guidance of a doctor.

3. Infection risk

Ibrutinib may cause suppression of immune system function and increase the risk of infection. During treatment with ibrutinib, patients may develop upper respiratory tract infection, pneumonia and other infectious symptoms, especially for patients with weak immune systems. During treatment, you should pay close attention to signs of infection such as fever, cough, and shortness of breath. If an infection occurs, the patient needs to seek medical attention promptly, and the doctor may adjust the treatment plan or use antibiotics for treatment.

4. Liver function monitoring

Ibrutinib is metabolized by the liver, so liver function needs to be monitored during use. Some patients may experience elevated liver enzymes while taking ibrutinib, and long-term abnormal liver function may lead to liver damage. Patients should undergo regular liver function tests, especially those with a history of liver disease. If symptoms such as jaundice, loss of appetite, and upper abdominal discomfort occur, they need to seek medical attention immediately.

5. Renal function assessment

Assessment of renal function is also very important when using ibrutinib. Although ibrutinib is less nephrotoxic, dose adjustment may be required in patients with renal impairment. Patients should have kidney function tests before starting treatment and monitor them regularly during treatment. If symptoms such as decreased urine output or edema occur, you should report it to your doctor in time.

6. Drug Interactions

Ibrutinib may interact with other medications, affecting their efficacy or increasing the risk of side effects. For example, when ibrutinib is used in combination with strong CYP3A inhibitors (such as ketoconazole), the plasma concentration of ibrutinib may increase and the occurrence of side effects may increase. Therefore, patients must inform their doctors about all other medications they are taking while taking ibrutinib, including prescription drugs, over-the-counter drugs, herbal remedies, and supplements.

7. Contraindications for pregnant and lactating patients

The impact of ibrutinib on pregnant women and fetuses has not yet been clarified. Animal experiments have found that ibrutinib may have adverse effects on the fetus, so the drug is prohibited for pregnant women. Breastfeeding women should avoid breastfeeding when taking ibrutinib because the drug may be passed to the baby through breast milk, causing potential harm. Therefore, women who are breastfeeding should consider discontinuing the drug or taking alternative treatment options.

8. Side Effect Management

Common side effects of ibrutinib include diarrhea, fatigue, headache, joint pain, etc., which are usually mild and can be managed through dose adjustment or symptomatic treatment. For serious side effects, such as persistent bleeding or severe infection, treatment may need to be paused or stopped until symptoms resolve. In addition, patients should communicate with their doctors regularly to detect and manage side effects in a timely manner.

Ibrutinib is an effective targeted drug with significant efficacy in the treatment of various B cell malignancies. However, side effects such as cardiovascular problems, bleeding, and infection may occur during use, so patients need to closely monitor their health during treatment and make necessary examinations and adjustments as recommended by their doctors. Through reasonable management and close follow-up, patients can reduce the impact of side effects during treatment and obtain the best treatment results.

Reference materials:https://www.imbruvica.com/